Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytisine for Co-occurring Smoking and Alcohol Use in PWH
NCT06790342Phase 3Not yet recruiting
- Sponsor
- University of Chicago
- Start
- Jul 2026
- Primary completion
- Jan 2028
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of cytisinicline in Tobacco Use Disorder (TUD), alcohol use disorder (AUD), sponsored by University of Chicago. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
cytisinicline
03
Conditions
Tobacco Use Disorder (TUD)alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT06790342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06790342.